Key result
The Health Impact Fund represents a novel mechanism to reward pharmaceutical companies based on the global health impact of their drugs, potentially improving access to novel anticoagulants.
The Health Impact Fund is proposed as a novel mechanism to reward pharmaceutical innovation based on health outcomes, using novel anticoagulants in atrial fibrillation as an illustrative example.
Answers are grounded in this paper and cite their sources.
Proposed incentive model should not alter anticoagulant prescribing; leaves open real-world feasibility of the Health Impact Fund.
Cardiovascular diseases represent the greatest burden of global disease. Spending on cardiovascular diseases is higher than for other diseases, with the majority being spent on drugs. Therefore, these drugs and these diseases are hugely important to health systems, society, and pharmaceutical companies. The Health Impact Fund represents a new mechanism by which pharmaceutical innovators would be rewarded on the basis of the health impact of their new drugs. This review illustrates the concept of the Health Impact Fund using the example of novel anticoagulants for prevention of stroke and thromboembolism in atrial fibrillation. By considering existing data and the current situation for novel anticoagulants, we suggest that epidemiologic data and modeling techniques can be used to predict future trends in disease and the health impact of new drugs. The Health Impact Fund may offer potential benefits to pharmaceutical companies, patients, and governments and warrants proper investigation.
No takes yet. Share an insight, caveat, or question.
Banerjee et al. (2014) conducted a review in Atrial Fibrillation. Health Impact Fund was evaluated. The Health Impact Fund represents a novel mechanism to reward pharmaceutical companies based on the global health impact of their drugs, potentially improving access to novel anticoagulants.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: